MaxiNovel Pharmaceuticals

MaxiNovel, founded in 2016, is a China-based biotech company specializing in innovative drug research with global intellectual property rights. The company focuses on first-in-class small molecule drug discovery, particularly in targeted therapy and immunotherapy. MaxiNovel's rapidly expanding product pipeline includes programs aimed at treating blood tumors, solid tumors, and autoimmune diseases. The company's research platforms encompass oral therapy, radiotherapy, imaging, and transdermal therapy. MaxiNovel operates R&D and operation centers in Shanghai, Guangzhou, Shenzhen, the United States, and Australia. One of its notable products, MAX 40070, is a topical JAK Tyk2 inhibitor currently in Phase I/II clinical trials for solid tumors and autoimmune skin diseases such as alopecia areata, atopic dermatitis, and psoriasis. The company aims to address safety concerns associated with long-term systemic drug exposure by developing topical treatments. MaxiNovel generates revenue through the development and commercialization of its proprietary drugs, targeting both domestic and international markets. The company serves a diverse clientele, including hospitals, research institutions, and pharmaceutical companies.

Keywords: biotech, drug discovery, targeted therapy, immunotherapy, blood tumors, solid tumors, autoimmune diseases, JAK inhibitors, clinical trials, global IP.